Crescita Therapeutics (CTX) Q2 2025 earnings summary

Executive summary

• Q2-2025 revenue rose to $6,233K from $4,088K year-over-year, driven by new manufacturing contracts and growth in the Skincare segment.

• Net income reached $798K, reversing a net loss of $(926)K in Q2-2024.

• Adjusted EBITDA improved to $964K from $(686)K, reflecting operational gains and a one-time termination payment.

• A mutual termination agreement with Croma contributed approximately $900K to revenue and cash.

Financial highlights

• Gross profit increased to $3,825K from $2,235K, with gross margin rising to 61.4% from 54.7% year-over-year.

• Operating expenses remained stable at $3,242K versus $3,279K.

• Cash and cash equivalents at quarter-end were $8,184K, down $354K from the previous quarter.

• Basic EPS was $0.04, compared to $(0.05) in Q2-2024.

Outlook and guidance

• Management is optimistic about growth prospects and is exploring strategic opportunities, including new partnerships for Pliaglis in Europe.